Serious erythromycin interactions caused by inhibition of drug metabolism in the liver.
Wynn
R L
RL
Department of Oral-Craniofacial Biological Sciences, Dental School, University of Maryland at Baltimore, USA.
D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000378:metabolism; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000378:metabolism* / Q000494:pharmacology; D000927:Anticonvulsants / Q000009:adverse effects / Q000378:metabolism; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000378:metabolism; D001569:Benzodiazepines; D001993:Bronchodilator Agents / Q000009:adverse effects / Q000378:metabolism; D002220:Carbamazepine / Q000009:adverse effects / Q000378:metabolism; D003024:Clozapine / Q000009:adverse effects / Q000378:metabolism; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004347:Drug Interactions; D004917:Erythromycin / Q000009:adverse effects* / Q000378:metabolism* / Q000494:pharmacology; D006634:Histamine H1 Antagonists / Q000009:adverse effects / Q000378:metabolism; D006801:Humans; D008099:Liver / Q000201:enzymology*; D013806:Theophylline / Q000009:adverse effects / Q000378:metabolism
D014151:Anti-Anxiety Agents; D000900:Anti-Bacterial Agents; D000927:Anticonvulsants; D014150:Antipsychotic Agents; D001993:Bronchodilator Agents; D065607:Cytochrome P-450 Enzyme Inhibitors; D006634:Histamine H1 Antagonists; D001569:Benzodiazepines; D002220:Carbamazepine; D004917:Erythromycin; D003577:Cytochrome P-450 Enzyme System; D013806:Theophylline; D003024:Clozapine